About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Meibomian Gland Disease Often associated with <em>Demodex</em> infestation Rosacea A common inflammatory skin condition

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-03 A potential candidate for meibomian gland disease TP-04 An investigational treatment for papulopustular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview

News & Presentations

Publications Corporate Governance

Stock Information

Other Resources

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Demodex Blepharitis Lyme Disease Meibomian Gland Disease Rosacea

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Pipeline Overview TP-03 TP-04 TP-05

Careers

Financials

SEC Filings

Filing date	Form	Description	View
Mar 14, 2022	10-K	Annual report which provides a comprehensive overview of the company for the past year	0001819790-22-000010.pdf 0001819790-22-000010.rtf 0001819790-22-000010.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 14, 2022	S-8	Securities offered to employees pursuant to employee benefit plans	0001819790-22-000012.pdf 0001819790-22-000012.rtf 0001819790-22-000012.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001519692-22-000002.pdf 0001519692-22-000002.rtf 0001519692-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001839516-22-000002.pdf 0001839516-22-000002.rtf 0001839516-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001788542-22-000002.pdf 0001788542-22-000002.rtf 0001788542-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001827564-22-000002.pdf 0001827564-22-000002.rtf 0001827564-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001841401-22-000002.pdf 0001841401-22-000002.rtf 0001841401-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001827584-22-000002.pdf 0001827584-22-000002.rtf 0001827584-22-000002.xls View HTML
Mar 11, 2022	4	Statement of changes in beneficial ownership of securities	0001827672-22-000002.pdf 0001827672-22-000002.rtf 0001827672-22-000002.xls View HTML
Feb 14, 2022	SC 13G/A	An amendment to the SC 13G filing	0000902664-22-001587.pdf 0000902664-22-001587.rtf 0000902664-22-001587.xls View HTML

Anchor Link for Quarterly Results

Data provided by Kaleidoscope.